Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

Now watching

Next video starts in : 7 Play

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio
Replay video
Up next

What to Watch Thursday: Campbell Soup Reports Quarterly Earnings

Unlock your personal NFL Now stream by signing in to NFL.com

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

by TheStreet 1:57 mins

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

by TheStreet 1:57 mins

Swiss drugmaker Roche Group announced it would buy Seragon Pharmaceuticals for $1.7 billion. It's the latest in a series of acquisitions for Roche, which bought Genia Technologies in June for $350 million and IQuum in May for $450 million. The Deal correspondent Andrew Bulkeley explains how Seragon's portfolio, which includes a focus on treatments for breast cancer, will impact Roche and its subsidiary Genentech going forward. Also, as the company widens its offerings of cancer treatments, Bulkeley reveals what other holes it may have in its portfolio and what other acquisitions it may make down the road.

TheStreet

Personal Finance

  1. 3:44

    A local man’s view on the real recovery of post-Katrina New Orleans

  2. A local man’s view on the real recovery of post-Katrina New Orleans

  3. 1:40

    How Much Money Do You Need to Be Rich? Kids' Answers Will Inspire You.

  4. 1:34

    Young people and startups are fueling New Orleans’ recovery after Hurricane Katrina

  5. 1:52

    Here's how smart investors will react to today's market drama

  6. 2:33

    In post-Katrina New Orleans, black men lift each other up

Market Movers

  1. 2:45

    Netflix starts Japan service as threats grow at home

  2. 16:26

    Stocks on the rebound; New jobs data released; Netflix expands as threats emerge

  3. 2:32

    CBS bringing limited live NFL to portable devices

  4. 2:56

    Judge sides with drivers in lawsuit against Uber

  5. 1:54

    H&R Block gains; Navistar falls; GoPro hurt by supplier; Target's 'Star Wars' help

  6. 3:02

    Crude oil's wild ride